Jianxin Chemical(SZ:300107)2023-04-14 16:00Financial Performance - The company's operating revenue for 2022 was ¥742,465,457.59, representing an increase of 18.20% compared to ¥628,149,906.61 in 2021[25]. - The net profit attributable to shareholders in 2022 was ¥61,274,503.04, a significant increase of 349.12% from ¥13,643,293.97 in 2021[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥52,741,320.76, up 909.87% from ¥5,222,597.50 in 2021[25]. - The basic earnings per share for 2022 was ¥0.1111, an increase of 349.80% compared to ¥0.0247 in 2021[25]. - The total assets at the end of 2022 were ¥1,667,011,929.77, reflecting a growth of 4.79% from ¥1,590,772,108.66 at the end of 2021[25]. - The net assets attributable to shareholders at the end of 2022 were ¥1,460,586,134.15, a slight increase of 1.24% from ¥1,442,694,269.98 at the end of 2021[25]. - The net cash flow from operating activities in 2022 was ¥163,360,835.84, a decrease of 14.79% from ¥191,719,039.31 in 2021[25]. - The company reported a weighted average return on equity of 4.23% in 2022, up from 0.94% in 2021[25]. - The total profit reached 64.22 million yuan, representing a significant growth of 434.56% year-on-year[46]. - The revenue from the fine chemical industry was ¥740,699,243.80, accounting for 99.76% of total revenue, with a year-on-year growth of 18.96%[54]. Dividend Distribution - The company plans to distribute a cash dividend of 0.6 RMB per 10 shares to all shareholders, based on a total of 551,731,068 shares[7]. - A cash dividend of CNY 0.60 per 10 shares (including tax) was proposed, totaling CNY 33,103,864.08, which represents 100% of the profit distribution amount[132]. - The total number of shares for the dividend distribution is 551,731,068, with no stock dividends or capital reserve transfers proposed[132]. Market and Competitive Position - The company aims to enhance R&D investment and optimize product structure to improve market competitiveness and safeguard profitability[3]. - The company will continue to focus on expanding both domestic and international markets to enhance its business presence and customer base[3]. - The company is focused on optimizing its industrial chain structure with a strategy of "expanding horizontally and strengthening vertically" to enhance market competitiveness[36]. - The company has developed a unique "one chain three bodies" product structure, focusing on intermediates for various industries, including pharmaceuticals and agriculture[42]. - The company is actively engaged in research and development of new products and technologies, aiming to improve overall production levels and promote clean production processes[36]. Risks and Challenges - The company faces market risks from rising overseas energy prices and high inflation, which may negatively impact export business and sales volume[3]. - The company acknowledges a risk of talent shortages in technical and management areas, which may hinder future development[5]. - The company is exposed to exchange rate risks due to a significant portion of exports being settled in USD, and it plans to monitor foreign exchange trends closely[5]. - The company emphasizes a low macro policy risk due to alignment with national industrial policy adjustments, allowing for strategic development adjustments as needed[3]. Environmental and Safety Compliance - The company is committed to increasing environmental investment to meet stricter regulatory standards and improve overall environmental awareness[6]. - The company has established comprehensive safety production regulations to mitigate risks associated with the use of flammable and explosive chemicals[7]. - The company has implemented a comprehensive environmental monitoring plan, approved by local authorities, to ensure compliance with pollution discharge standards[148]. - The company has established a compliance evaluation report for environmental regulations, assessing adherence to legal requirements annually[144]. - The company has not reported any significant environmental pollution incidents or violations in the past year[144]. Research and Development - The company is dedicated to improving its R&D capabilities and product competitiveness through increased management efficiency and strategic market expansion[3]. - The company's R&D investment amounted to ¥31,810,219.32 in 2022, representing 4.28% of total revenue, a slight decrease from 4.50% in 2021[68]. - The company has invested 50 million RMB in R&D for new technologies aimed at improving production efficiency[111]. - The company is exploring capital market functions to enhance its development and is considering issuing stocks or other capital operations to optimize its industrial layout[87]. Corporate Governance - The company has established a robust internal governance and human resource management system to enhance operational transparency and protect investor interests[52]. - The company maintains transparency in governance, ensuring equal rights for all shareholders and compliance with relevant laws and regulations[94]. - The internal audit system is in place to ensure compliance and effective risk management, with no significant issues reported in internal controls[97]. - The company has established a performance evaluation and incentive mechanism for senior management, linking their compensation to company performance[135]. Employee Management - The company has implemented an employee incentive plan, benefiting 87 individuals, to align personal goals with long-term corporate development[53]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.7251 million CNY[114]. - The company has established a salary management system that considers both internal fairness and external competitiveness, with a focus on high-responsibility and high-risk positions[125]. - The total number of employees at the end of the reporting period is 930, with 705 in production, 14 in sales, 135 in technical roles, 13 in finance, and 63 in administration[123]. Future Outlook - In 2023, the company plans to focus on traditional industry upgrades and leverage opportunities from "China Manufacturing 2025" and "carbon peak and carbon neutrality" initiatives[86]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion RMB[111]. - The company plans to enhance its distribution network, with an investment of 30 million RMB to improve logistics and supply chain operations[111]. - The company aims to enhance product value and achieve overall industry chain development by introducing new products related to dye intermediates, new material intermediates, and pharmaceutical intermediates[86].